Border Patrol agents flooding immigrant neighborhoods, showing dramatic force, storming Home Depot parking lots and preying ...

Blueprint Medicines Corporation BPMC reported a fourth-quarter 2023 loss of $1.82 per share, narrower than the Zacks Consensus Estimate of a loss of $2.04 and a loss of $2.65 in the year-ago quarter.

In trading on Thursday, shares of Blueprint Medicines Corp (Symbol: BPMC) crossed below their 200 day moving average of $49.81, changing hands as low as $49.72 per share. Blueprint Medicines Corp ...

VSee Health (VSEE) announces an upcoming webinar today with Novant Health Urgent Care. The event will focus on how healthcare organizations can ...

Blueprint Medicines' primary revenue driver is Ayvakit, approved for various forms of Systemic Mastocytosis (SM) and showing strong growth, with 2024 revenues at $479m. The company projects Ayvakit to ...

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. KANSAS CITY, Mo. — Kansas City Public ...

After releasing their first single for Run for Cover in 2021, and following it with a couple more over the past few months, LANNDS, the Jacksonville, FL-based duo of Rania Woodard and Brian Squillace, ...

Kate Haviland is CEO of Blueprint Medicines. From the Boston Business Journal. Sanofi is acquiring Blueprint Medicines Corp. and its rare immunology disease treatment, which is already approved in the ...

CAMBRIDGE, Mass., July 14, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer ...